27494909|t|Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi
27494909|a|No data are available on bone metabolism in infants exposed to tenofovir during breastfeeding. We investigated bone metabolism markers in the first year of life in infants from mothers who received tenofovir, lamivudine and efavirenz during pregnancy and 12 months of breastfeeding in a national Option B+ programme in Malawi. Serum samples collected at 6 and 12 months in tenofovir - exposed infants and in a small sample of tenofovir - unexposed infants from the same clinical centre were analysed in batches for levels of bone-specific alkaline phosphatase (BAP; marker of bone formation) and of C-terminal telopeptide of type I collagen (CTX; marker of bone resorption). Overall, 136 tenofovir - exposed infants were evaluated. No infant had at either timepoint CTX values above the upper normal limit, while most of them had at 6 and 12 months levels of BAP above the upper normal limit for the age range. Levels of bone markers showed no differences by gender and no association with growth parameters. Tenofovir - unexposed and - exposed children had similar mean levels of bone markers at 6 months (CTX: 0.62 versus 0.55 ng/mL, P = 0.122; BAP: 384 versus 362 U/L, P = 0.631). No significant association between treatment with tenofovir and CTX or BAP levels was found. The high levels of BAP, coupled to the normal levels observed for CTX, might reflect primarily skeletal growth. Potential negative effects of prolonged exposure to tenofovir through breastfeeding cannot however be excluded and longitudinal studies that evaluate bone mineralization status in children enrolled in Option B+ programmes are warranted.
27494909	10	14	bone	T017	UMLS:C0391978
27494909	15	22	markers	T201	UMLS:C0005516
27494909	28	38	population	T098	UMLS:C1257890
27494909	78	91	breastfeeding	T038	UMLS:C0006147
27494909	95	104	tenofovir	T103	UMLS:C0384228
27494909	138	144	Malawi	T082	UMLS:C0024548
27494909	208	217	tenofovir	T103	UMLS:C0384228
27494909	225	238	breastfeeding	T038	UMLS:C0006147
27494909	272	279	markers	T201	UMLS:C0005516
27494909	343	352	tenofovir	T103	UMLS:C0384228
27494909	354	364	lamivudine	T103	UMLS:C0209738
27494909	369	378	efavirenz	T103	UMLS:C0674428
27494909	386	395	pregnancy	T038	UMLS:C0032961
27494909	413	426	breastfeeding	T038	UMLS:C0006147
27494909	464	470	Malawi	T082	UMLS:C0024548
27494909	472	477	Serum	T031	UMLS:C0229671
27494909	518	527	tenofovir	T103	UMLS:C0384228
27494909	571	580	tenofovir	T103	UMLS:C0384228
27494909	583	600	unexposed infants	T098	UMLS:C2349018
27494909	615	630	clinical centre	T092	UMLS:C0442592
27494909	636	644	analysed	T062	UMLS:C0936012
27494909	670	704	bone-specific alkaline phosphatase	T103	UMLS:C0312399
27494909	706	709	BAP	T103	UMLS:C0312399
27494909	711	717	marker	T201	UMLS:C0005516
27494909	721	735	bone formation	T038	UMLS:C0029433
27494909	744	785	C-terminal telopeptide of type I collagen	T103	UMLS:C0631180
27494909	787	790	CTX	T103	UMLS:C0631180
27494909	792	798	marker	T201	UMLS:C0005516
27494909	802	817	bone resorption	T038	UMLS:C0005974
27494909	833	842	tenofovir	T103	UMLS:C0384228
27494909	845	860	exposed infants	T098	UMLS:C2348484
27494909	866	875	evaluated	T058	UMLS:C0220825
27494909	911	914	CTX	T103	UMLS:C0631180
27494909	1004	1007	BAP	T103	UMLS:C0312399
27494909	1066	1070	bone	T017	UMLS:C0391978
27494909	1071	1078	markers	T201	UMLS:C0005516
27494909	1154	1163	Tenofovir	T103	UMLS:C0384228
27494909	1166	1175	unexposed	T098	UMLS:C2349018
27494909	1182	1198	exposed children	T098	UMLS:C2348484
27494909	1226	1230	bone	T017	UMLS:C0391978
27494909	1231	1238	markers	T201	UMLS:C0005516
27494909	1252	1255	CTX	T103	UMLS:C0631180
27494909	1292	1295	BAP	T103	UMLS:C0312399
27494909	1364	1373	treatment	T058	UMLS:C0087111
27494909	1379	1388	tenofovir	T103	UMLS:C0384228
27494909	1379	1388	tenofovir	T103	UMLS:C0384228
27494909	1393	1396	CTX	T103	UMLS:C0631180
27494909	1400	1403	BAP	T103	UMLS:C0312399
27494909	1441	1444	BAP	T103	UMLS:C0312399
27494909	1488	1491	CTX	T103	UMLS:C0631180
27494909	1517	1525	skeletal	T022	UMLS:C0037253
27494909	1526	1532	growth	T038	UMLS:C0018270
27494909	1544	1552	negative	T033	UMLS:C0205160
27494909	1586	1595	tenofovir	T103	UMLS:C0384228
27494909	1586	1595	tenofovir	T103	UMLS:C0384228
27494909	1604	1617	breastfeeding	T038	UMLS:C0006147
27494909	1604	1617	breastfeeding	T038	UMLS:C0006147
27494909	1649	1669	longitudinal studies	T062	UMLS:C0023981
27494909	1675	1683	evaluate	T058	UMLS:C0220825
27494909	1684	1703	bone mineralization	T038	UMLS:C2350989